| [1] |
LEWDEN C, SALMON D, MORLAT P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS[J]. Int J Epidemiol, 2005, 34(1): 121-130. DOI: 10.1093/ije/dyh307. |
| [2] |
LEONE S, LORENZINI P, COZZI-LEPRI A, et al. Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: Data from the ICONA Foundation Cohort Study[J]. Eur J Clin Microbiol Infect Dis, 2019, 38(10): 1857-1865. DOI: 10.1007/s10096-019-03618-8. |
| [3] |
GONZALEZ SA, TALAL AH. Hepatitis C virus in human immunodeficiency virus-infected individuals: An emerging comorbidity with significant implications[J]. Semin Liver Dis, 2003, 23(2): 149-166. DOI: 10.1055/s-2003-39946. |
| [4] |
Acquired Immunodeficiency Syndrome and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2021 edition)[J]. Chin J Intern Med, 2021, 60(12): 1106-1128. DOI: 10.3760/cma.j.cn112138-20211006-00676. |
| [5] |
SARIN SK, KUMAR A, CHAWLA YK, et al. Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment[J]. Hepatol Int, 2007, 1(3): 398-413. DOI: 10.1007/s12072-007-9010-9. |
| [6] |
ALVAREZ DH, MARINO CA, GARCIA RJ. Non-cirrhotic portal hypertension in human immunodeficiency virus-infected patients: A new challenge in antiretroviral therapy era[J]. Open AIDS J, 2011, 5: 59-61. DOI: 10.2174/1874613601105010059. |
| [7] |
HADDOW LJ, WOOD CW, AINSWORTH JG. Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity[J]. Int J STD AIDS, 2007, 18(5): 343-346. DOI: 10.1258/095646207780749790. |
| [8] |
QIN F, JIANG J, QIN C, et al. Liver damage in patients living with HIV on antiretroviral treatment with normal baseline liver function and without HBV/HCV infection: An 11-year retrospective cohort study in Guangxi, China[J]. BMJ Open, 2019, 9(4): e23140. DOI: 10.1136/bmjopen-2018-023140. |
| [9] |
SULKOWSKI MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors[J]. Clin Infect Dis, 2004, 38(Suppl 2): S90-S97. DOI: 10.1086/381444. |
| [10] |
CHANG PE, MIQUEL R, BLANCO JL, et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy[J]. Am J Gastroenterol, 2009, 104(7): 1707-1714. DOI: 10.1038/ajg.2009.165. |
| [11] |
de FRANCHIS R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022. |
| [12] |
HE FL, OU XJ, WANG M, et al. Value of hepatic venous pressure gradient in predicting clinical end events in liver cirrhosis[J]. J Clin Hepatol, 2020, 36(9): 1931-1935. DOI: 10.3969/j.issn.1001-5256.2020.09.004. |
| [13] |
CHANG PE, GARCIA-PAGAN JC. Idiopathic noncirrhotic portal hypertension in HIV-infected patients[J]. Clin Infect Dis, 2010, 50(1): 127-128; author reply 128-129. DOI: 10.1086/649009. |
| [14] |
VISPO E, MORENO A, MAIDA I, et al. Noncirrhotic portal hypertension in HIV-infected patients: Unique clinical and pathological findings[J]. AIDS, 2010, 24(8): 1171-1176. DOI: 10.1097/QAD.0b013e3283389e26. |
| [15] |
DHAR A, SADIQ F, ANSTEE QM, et al. Thrombin and factor Xa link the coagulation system with liver fibrosis[J]. BMC Gastroenterol, 2018, 18(1): 60. DOI: 10.1186/s12876-018-0789-8. |
| [16] |
CESARI M, SCHIAVINI M, MARCHETTI G, et al. Noncirrhotic portal hypertension in HIV-infected patients: A case control evaluation and review of the literature[J]. AIDS Patient Care STDS, 2010, 24(11): 697-703. DOI: 10.1089/apc.2010.0160. |
| [17] |
ZHAO LH, JIA JD. Etiological diagnosis and standard treatment of portal hypertension should be taken seriously[J]. J Clin Hepatol, 2019, 35(1): 10-12. DOI: 10.3969/j.issn.1001-5256.2019.01.001. |
DownLoad: